Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Medtronic
Novartis
Covington
Cipla
Farmers Insurance
Dow
Fuji
Moodys

Generated: October 20, 2017

DrugPatentWatch Database Preview

OMONTYS Drug Profile

« Back to Dashboard

Which patents cover Omontys, and what generic Omontys alternatives are available?

Omontys is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and thirteen patent family members in thirty-two countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Summary for Tradename: OMONTYS

US Patents:6
Applicants:1
NDAs:1
Clinical Trials: see list18
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OMONTYS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-006Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-006Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-007Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-001Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OMONTYS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,391Peptides that bind to the erythropoietin receptor► Subscribe
7,855,175Peptides that bind to the erythropoietin receptor► Subscribe
8,592,365Spacer moiety for poly(ethylene glycol) modified peptide based compounds► Subscribe
7,906,485Erythropoietin receptor peptide formulations and uses► Subscribe
8,729,030Peptides that bind to the erythropoietin receptor► Subscribe
8,324,159Erythropoietin receptor peptide formulations and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OMONTYS

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004101611► Subscribe
Denmark1629007► Subscribe
Spain2395413► Subscribe
South Korea20120094001► Subscribe
Canada2525497► Subscribe
South Africa200509971► Subscribe
South Korea20060022655► Subscribe
South Korea20080021115► Subscribe
Serbia51130► Subscribe
Australia2004238364► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Covington
Boehringer Ingelheim
Merck
AstraZeneca
Cantor Fitzgerald
McKesson
Chinese Patent Office
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot